CHAPTER 137 HUMAN LEUKOCYTE AND PLATELET ANTIGENS Flashcards
Two major classes of HLA and their examples
class I (A, B, and C loci)
class II (DR, DQ, and DP loci)
primarily expressed on B cells and other antigen-presenting cells such as dendritic cells, endothelial cells, and monocytes
class II (DR, DQ, and DP loci)
human leukocyte antigens play key roles in: (3)
1) HSC transplantation acceptance/ rejection
2) allosensitization to non-leukoreduced blood transfusions leading to platelet transfusion refractoriness,
3) lesser, in solid- organ transplantation
HLA are highly polymorphic glycoproteins encoded by a region of genes known as the major histocompatibility complex (MHC) located on
chromosome 6p21
T/F: After ABO antigens, HLA antigens are the major barrier to transplantation.
True
Are ubiquitous and present on most nucleated somatic cells
Class I antigens
Exhibit more restricted distribution, with varying levels of expression on B cells, dendritic cells, monocytes, macrophages, and endothelial cells.
Class II antigens
T/F: class II antigens can be induced on many cell types through activation.
True
nonclassical class Ib antigens
- much less polymorphic
- function less understood
HLA-E, HLA-F, and HLA-G
Antibodies recognizing platelet-specific alloantigens have been discovered in three clinical situations:
- mothers who give birth to infants with FNAIT;
- patients who develop dramatic thrombocytopenia after blood transfusion (PTP);
- and patients who have received multiple transfusions.
principal cause of immunologic platelet transfusion refractoriness
class I HLA antigens
T/F: occasionally patients receiving multiple platelet transfusions will develop antibodies to platelet specific alloantigens.
True
If platelet transfusion refractoriness does develop because of platelet- specific antibodies, compatible platelet products may be identified by: (2)
1) using either platelet crossmatching or
2) by accessing family member or other HPA-typed donors who are compatible with the patient’s antibodies
T/F: Antibodies against some HPA-allelic determinants can inhibit platelet function.
True
_____can inhibit clot retraction and platelet aggregation, presumably because they block the binding of GPIIb/IIIa (α β ) (CD41/CD61) to fibrinogen. –> identify the type of platelet function disease
- Anti–HPA-1 alloantibodies,
- GLANZMANN
______, lack platelet GPIb-V-IX (CD 42a-c)
Bernard-Soulier syndrome
_______ can completely inhibit aggregation of HPA-4 platelets that are homozygous for the allele recognized by the alloantibodies because the epitope is in close proximity to the RGD (arginine-glycine-aspartic acid peptide sequence)
Anti–HPA-4 alloantibodies
T/F: other anti–HPA-alloantibodies, such as those specific for HPA-3, may not significantly interfere with platelet function but nonetheless can cause Fc-mediated platelet destruction and immune thrombocytopenia
TRUE
result from transfusion of antibodies to recipient HPA
passive alloimmune thrombocytopenia
Transfusion of blood components containing antibodies to ____ and _____ have been reported to result in significant thrombocytopenia for 1 to 2 weeks.
HPA-1a and -5b
T/F: Many of the best-documented platelet-specific antibodies detected in such patients are directed against platelet antigens whose phenotypic frequencies are less than 30% in the blood-donor population.
Matching Type:
1. Anti–HPA-1 alloantibodies
2. Anti–HPA-3 alloantibodies
3. Anti–HPA-4 alloantibodies
4. Anti–HPA-1a and 5b alloantibodies
a. inhibit aggregation of HPA-4 platelets that are homozygous for the allele recognized by the alloantibodies because the epitope is in close proximity to the RGD
b. result in significant thrombocytopenia for 1 to 2 weeks
c. can inhibit clot retraction and platelet aggregation, presumably because they block the binding of GPIIb/IIIa (α β ) (CD41/CD61)
d. can cause Fc-mediated platelet destruction and immune thrombocytopenia
1, c
2, d
3, a
4, b
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
The earliest.
Involved mixing of patient serum with normal platelets and used platelet function-dependent end points such as α-granule release, aggregation, or agglutination.
Phase I
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
the only major phase I assay remaining in wide use today
serotonin release assay
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
detect either surface or total platelet-associated immunoglobulin on patient platelets or on normal platelets after sensitization with patient serum
phase II tests
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
An example of a phase II assay in wide use today:
solid-phase red cell adherence test, used for platelet crossmatching
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
developed in which the binding of antibodies to isolated platelet surface GPs is detected.
Phase III assays
TESTING FOR PLATELET-SPECIFIC ANTIGENS AND ANTIBODIES
detect alloantibodies in the evaluation of suspected FNAIT and PTP, as well as autoantibodies in some cases of ITP
Phase III assays
Examples of phase III assays (2)
- monoclonal antibody immobilization of platelet antigens assay (MAIPA)
- modified antigen capture ELISA (MACE)
because of limited access to rare typing sera and the need to establish platelet typing in patients with very few platelets, they have been largely supplanted by _______
molecular typing using methods based on PCR
Alleles present at gene frequencies greater than 2 percent within the population are designated as ____
public alleles
These alleles are more likely to encode alloantigens involved in PTP.
public alleles